Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

NCT04451837 on ClinicalTrials.gov · last registry update 2025-07-16

Closed to new participants; the 200 already enrolled are still being followed. The sponsor logged completion for 15 December 2021. Primary outcome, as filed: Hba1c. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Region Skane
Sponsor type: Other
Enrollment: 200
Started: 2020-09-10
Primary completion: 2021-12-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Hba1c

Conditions studied

Type2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.